Zydus Cadila Gets Tentative Usfda Nod To Market Anti-Cancer Drug
Drug Firm Zydus Cadila On Thursday Said It Has Received Tentative Approval From The Us Health Regulator To Market Anti-Cancer Drug Palbociclib Capsules. Zydus Cadila Has Received Tentative Approval From The Us Food And Drug Administration (Usfda) To Market Palbociclib Capsules In The Strengths Of 75 Mg, 100 Mg, And 125 Mg, Zydus Cadila, Part Of The Cadila Healthcare Group, Said In A Regulatory Filing.Palbociclib Is An Anti-Cancer Medicine That Interferes With The Growth And Spread Of Cancer Cells In The Body. The Company Said The Newly Approved Medication Will Be Manufactured At The Group'S Formulation Manufacturing Facility At The Sez, Ahmedabad.The Group Now Has 302 Approvals And Has So Far Filed Over 390 Abbreviated New Drug Applications Since The Commencement Of The Filing Process In Financial Year 2003-04. Shares Of Cadila Healthcare Were Trading 1.07 Per Cent Lower At Rs 379.80 On Bse.
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
